Van ECK Associates Corp Has $21.83 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Van ECK Associates Corp trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 111,088 shares of the medical research company’s stock after selling 9,751 shares during the period. Van ECK Associates Corp’s holdings in IQVIA were worth $21,829,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the third quarter worth approximately $27,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $33,000. Assetmark Inc. lifted its holdings in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Finally, Concord Wealth Partners acquired a new position in IQVIA in the third quarter valued at approximately $57,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Robert W. Baird cut their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Stock Down 1.2 %

Shares of IQV stock opened at $193.65 on Friday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a fifty day moving average of $200.59 and a 200-day moving average of $218.51. The company has a market capitalization of $35.15 billion, a price-to-earnings ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.